The Solution to the Obesity Epidemic May be Found in Psilocybin
Tue June 2, 2020
Houston, Texas--(Newsfile Corp. - June 2, 2020) - The global obesity epidemic is bursting at the seams.
In fact, according to the World Health Organization (WHO) obesity has tripled in size over the last 50 years. In 2016, they note, 1.9 billion adults were overweight around the world. Of those, 650 million were considered obese. Just in the U.S., nearly 34% of adults and up to 20% of children are obese. It's greatly out of control.
By 2030, almost half of U.S. adults will be considered obese.
Along with it comes complications with heart disease, stroke, type 2 diabetes, and several types of cancer. In fact, according to Energy Balance and Obesity: What are the Main Drivers? "There is convincing evidence for a role of obesity as a causal factor for many types of cancer including colorectum, endometrium, kidney, oesophagus, postmenopausal breast, gallbladder, pancreas, gastric cardia, liver, ovary, thyroid, meningioma, multiple myeloma, and prostate cancers."
However, a solution may be found in psychedelics such as psilocybin, which activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."
In short, psilocybin may be able to meet a very large unmet need for compounds that can potentially lead to safe weight loss, and help improve metabolic health.
Psilocybin May Help Address the Global Obesity Epidemic
NeonMind Biosciences Inc., a majority owned subsidiary of Yield Growth Corp. (BOSQF) (CSE: BOSS) (OTCQB: BOSQF) has taken further steps towards commencing its clinical studies to confirm whether psilocybin (a compound in psychedelic mushrooms) is an effective treatment for food cravings and weight loss.
At the moment, the company is the preclinical stage of developing a psilocybin-based product that can be used to treat obesity and assist with weight loss. In addition, it has also filed for a U.S. provisional patent application to protect the invention that the administration of psilocin or psilocybin results in overall weight loss in individuals by reducing food cravings, counteracting compulsive eating, and improving the quality of diet by empowering the mind to select low-calorie foods.
The pending patent also covers the use of micro-dose administration of psilocin or psilocybin or both compounds to have the additional weight loss effects of increasing metabolism, treating or regulating diabetes, reducing blood glucose, and reducing susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus and other illnesses associated with obesity.
NeonMind Biosciences Inc. has also engaged Translational Life Sciences Inc. to conduct the study and that TLS had completed the design of a study to confirm whether psilocybin (found in psychedelic mushrooms) is an effective treatment for weight loss and food craving.
TLS has identified a source of synthetically created psilocybin, manufactured by a licensed laboratory, for use in the NeonMind studies. Also, NeonMind has identified a laboratory where the studies can be carried out. Before the psilocybin can be ordered and before NeonMind can enter into an agreement with the Lab, the Lab must first obtain an exemption from the Canadian Minister of Health pursuant to Subsection 56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 by the researchers at the Lab to allow them to use psilocybin, a controlled substance, in research studies. NeonMind expects the exemption to be granted within a few months. Researchers at the Lab have previously obtained other exemptions for research involving controlled substances.
TLS has provided an estimate of $250,000 as a budget for the study and an estimated time frame of 6 months to complete the study, with valuable data anticipated to be available within the first few months. TLS estimates that all necessary approvals can be obtained so that the study can commence in the fall of 2020. NeonMind plans to fund the study using previous capital raised and from the proceeds of a planned initial public offering of NeonMind, for which due diligence is currently underway with a Canadian investment dealer.
For more information, visit the company's website at https://yieldgrowth.com.
https://seekingalpha.com/pr/17888803-solution...psilocybin
Tue June 2, 2020
Houston, Texas--(Newsfile Corp. - June 2, 2020) - The global obesity epidemic is bursting at the seams.
In fact, according to the World Health Organization (WHO) obesity has tripled in size over the last 50 years. In 2016, they note, 1.9 billion adults were overweight around the world. Of those, 650 million were considered obese. Just in the U.S., nearly 34% of adults and up to 20% of children are obese. It's greatly out of control.
By 2030, almost half of U.S. adults will be considered obese.
Along with it comes complications with heart disease, stroke, type 2 diabetes, and several types of cancer. In fact, according to Energy Balance and Obesity: What are the Main Drivers? "There is convincing evidence for a role of obesity as a causal factor for many types of cancer including colorectum, endometrium, kidney, oesophagus, postmenopausal breast, gallbladder, pancreas, gastric cardia, liver, ovary, thyroid, meningioma, multiple myeloma, and prostate cancers."
However, a solution may be found in psychedelics such as psilocybin, which activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."
In short, psilocybin may be able to meet a very large unmet need for compounds that can potentially lead to safe weight loss, and help improve metabolic health.
Psilocybin May Help Address the Global Obesity Epidemic
NeonMind Biosciences Inc., a majority owned subsidiary of Yield Growth Corp. (BOSQF) (CSE: BOSS) (OTCQB: BOSQF) has taken further steps towards commencing its clinical studies to confirm whether psilocybin (a compound in psychedelic mushrooms) is an effective treatment for food cravings and weight loss.
At the moment, the company is the preclinical stage of developing a psilocybin-based product that can be used to treat obesity and assist with weight loss. In addition, it has also filed for a U.S. provisional patent application to protect the invention that the administration of psilocin or psilocybin results in overall weight loss in individuals by reducing food cravings, counteracting compulsive eating, and improving the quality of diet by empowering the mind to select low-calorie foods.
The pending patent also covers the use of micro-dose administration of psilocin or psilocybin or both compounds to have the additional weight loss effects of increasing metabolism, treating or regulating diabetes, reducing blood glucose, and reducing susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus and other illnesses associated with obesity.
NeonMind Biosciences Inc. has also engaged Translational Life Sciences Inc. to conduct the study and that TLS had completed the design of a study to confirm whether psilocybin (found in psychedelic mushrooms) is an effective treatment for weight loss and food craving.
TLS has identified a source of synthetically created psilocybin, manufactured by a licensed laboratory, for use in the NeonMind studies. Also, NeonMind has identified a laboratory where the studies can be carried out. Before the psilocybin can be ordered and before NeonMind can enter into an agreement with the Lab, the Lab must first obtain an exemption from the Canadian Minister of Health pursuant to Subsection 56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 by the researchers at the Lab to allow them to use psilocybin, a controlled substance, in research studies. NeonMind expects the exemption to be granted within a few months. Researchers at the Lab have previously obtained other exemptions for research involving controlled substances.
TLS has provided an estimate of $250,000 as a budget for the study and an estimated time frame of 6 months to complete the study, with valuable data anticipated to be available within the first few months. TLS estimates that all necessary approvals can be obtained so that the study can commence in the fall of 2020. NeonMind plans to fund the study using previous capital raised and from the proceeds of a planned initial public offering of NeonMind, for which due diligence is currently underway with a Canadian investment dealer.
For more information, visit the company's website at https://yieldgrowth.com.
https://seekingalpha.com/pr/17888803-solution...psilocybin
